INOVIO PHARMACEUTICALS, INC.

INOVIO Pharmaceuticals, Inc. (Nasdaq: INO) is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to treat and protect people from human papillomavirus-associated diseases, cancer, and infectious diseases. The company's website is www.inovio.com.

INOVIO's platform harnesses the power of in vivo protein production through optimized design and delivery of DNA medicines that teach the body's cells to manufacture disease-fighting proteins. The company uses proprietary technology to design DNA plasmids, which are small circular DNA molecules that function like software enabling cells to produce specific proteins targeting disease. These plasmids are delivered using INOVIO's proprietary CELLECTRA devices, which employ electroporation technology to increase cellular uptake without requiring chemical adjuvants, lipid nanoparticles, or viral vectors.

The company's lead candidate is INO-3107 for treating recurrent respiratory papillomatosis, a chronic rare disease characterized by tumor growth in the respiratory tract caused primarily by HPV-6 and HPV-11. In December 2025, the FDA accepted INOVIO's Biologic License Application for INO-3107 under the accelerated approval program with a target review date of October 30, 2026. Clinical data demonstrates that 81 percent of patients experienced a reduction of one or more surgeries at Year 1 post-treatment, with 91 percent continuing to experience such reduction by Year 2.

INOVIO's pipeline includes INO-3112 for oropharyngeal squamous cell carcinoma in combination with checkpoint inhibitors, INO-5401 for glioblastoma and cancer prevention in BRCA mutation carriers, and VGX-3100 for HPV-related cervical and anal dysplasia. The company is also developing infectious disease candidates including INO-4800 for COVID-19, INO-4201 as an Ebola booster vaccine, and INO-6160 as an HIV prophylactic vaccine. Emerging technology platforms include DNA-encoded monoclonal antibodies, DNA-encoded proteins, and DNA-launched nanoparticles.

INOVIO has administered its DNA medicines over 19,000 times across nearly 6,000 clinical trial participants. The company collaborates with partners including AstraZeneca, Coherus Biosciences, the National Institutes of Health, DARPA, and academic institutions. INOVIO has not generated product revenues and does not expect material revenues unless it obtains marketing approval and successfully commercializes its candidates.